SMTL ID : 6q2t.2 (1 other biounit)

Human sterol 14a-demethylase (CYP51) in complex with the functionally irreversible inhibitor (R)-N-(1-(3-chloro-4'-fluoro-[1,1'-biphenyl]-4-yl)-2-(1H-imidazol-1-yl)ethyl)-4-(5-(3-fluoro-5-(5-fluoropyrimidin-4-yl)phenyl)-1,3,4-oxadiazol-2-yl)benzamide

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.80 Å

Oligo State

monomer

Ligands

1 x HEM: PROTOPORPHYRIN IX CONTAINING FE(Non-covalent)

HEM.1: 25 residues within 4Å: Chain A: Y.74, Y.88, F.95, K.99, L.251, A.254, G.255, T.258, S.259, P.319, I.320, M.323, R.325, P.384, F.385, G.386, R.389, H.390, R.391, C.392, I.393, G.394, F.397, A.398 Ligands: PJM.2 15 PLIP interactions: 15 interactions with chain A, Hydrophobic interactions: A:K.99, A:L.251, A:A.254, A:T.258, A:P.319, A:F.385, A:F.385, A:I.393, A:F.397, A:A.398 Hydrogen bonds: A:H.390 Salt bridges: A:K.99, A:R.325, A:H.390 Metal complexes: A:C.392

1 x PJM: N-[(1R)-1-(3-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-(1H-imidazol-1-yl)ethyl]-4-{5-[3-fluoro-5-(5-fluoropyrimidin-4-yl)phenyl]-1,3,4-oxadiazol-2-yl}benzamide(Non-covalent)

PJM.2: 20 residues within 4Å: Chain A: F.48, V.73, Y.74, L.77, T.78, F.82, F.95, L.102, H.179, W.182, M.247, G.250, L.251, L.253, A.254, T.258, I.320, Q.343, M.430 Ligands: HEM.1 10 PLIP interactions: 10 interactions with chain A Hydrophobic interactions: A:Y.74, A:T.78, A:F.82, A:F.82, A:F.95, A:W.182, A:W.182, A:A.254 pi-Stacking: A:F.177, A:W.182

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Friggeri, L. et al., Validation of Human Sterol 14 alpha-Demethylase (CYP51) Druggability: Structure-Guided Design, Synthesis, and Evaluation of Stoichiometric, Functionally Irreversible Inhibitors. J.Med.Chem. (2019)

Release Date

2019-11-13

Peptides

Lanosterol 14-alpha demethylase: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

Lanosterol 14-alpha demethylase

Related Entries With Identical Sequence